Time to second progression (PFS2) in patients from TITAN with metastatic castration-sensitive prostate cancer by first subsequent therapy (hormonal vs. taxane).

ASCO-GU 2020 Congress – Abstract No. 82. Agarwal N. et al

Conclusion:

“The addition of APA to ADT for treatment of mCSPC results in risk reduction of 2nd progression regardless of choice of hormonal or taxane as the 1st life-prolonging subsequent therapy.”

 

Quelle:

https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2020-02/GU20-Proceedings-corrected-reduced.pdf?null